BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

...not associated with differences in outcomes in adults Lunenfeld-Tanenbaum Research Institute e22525 TPR-TrkA; EML1-TrkB; KANK1-TrkB; EML4-TrkC...
BioCentury | Jun 7, 2018
Preclinical News

Targeting tumor cilia could reverse resistance to kinase inhibitors

...in three cell lines with acquired resistance to kinase inhibitors -- EML4-ALK oncogenic fusion protein (EML4-ALK)-positive...
BioCentury | Jul 27, 2017
Translation in Brief

Better glioma mouse models

...EML4-ALK oncogenic fusion protein (EML4-ALK) and produced lung tumors in mice that closely recapitulated human EML4-ALK...
...Writer entrectinib Ignyta Inc. Memorial Sloan Kettering Cancer Center Nerviano Medical Sciences s.r.l. CRISPR-associated protein 9 (Cas9) EML4-ALK oncogenic fusion protein (EML4-ALK) Neurotrophic...
BioCentury | Oct 13, 2016
Strategy

Exosomes in the zone

...The lung cancer diagnostic, launched in January, is a blood test for markers of the EML4-ALK...
...of Defense, Washington, D.C. Targets and Compounds EGFR - Epidermal growth factor receptor EML4-ALK - EML4-ALK...
BioCentury | Apr 11, 2016
Tools & Techniques

Stepping on the scale

...The drug targets a fusion gene containing portions of the echinoderm microtubule-associated protein like 4 (EML4...
BioCentury | Apr 7, 2016
Tools & Techniques

Sexy sequencing

...in non-smokers with lung cancer, KRAS mutations in colon cancer, or chromosomal translocations such as EML4-ALK...
...AstraZeneca plc 's Iressa gefitinib for EGFR mutations or Pfizer Inc. 's Xalkori crizotinib for EML4-ALK...
...Cytotoxic T-lymphocyte associated protein 4 EGFR - Epidermal growth factor receptor EML4-ALK - EML4-ALK...
BioCentury | Feb 15, 2016
Emerging Company Profile

Platelet portrait

...Umea, Sweden VU University Medical Center, Amsterdam, the Netherlands References Nilsson, R.J.A., et al. "Rearranged EML4-ALK...
BioCentury | Oct 5, 2015
Clinical News

EML4-ALK assay: Clinical trial data

...that Exosome’s ExoDx Lung ALK assay had 88% sensitivity and 100% specificity for differentiating between EML4-ALK...
...test (LDT) is performed at Exosome’s CLIA-certified laboratory. Exosome Diagnostics Inc. , Cambridge, Mass. Product: EML4-ALK...
...from a blood sample to detect EML4-ALK mutation and oncogenic fusion protein transcripts Indication: Detect EML4-ALK...
BioCentury | Sep 3, 2015
Distillery Therapeutics

Therapeutics: Anaplastic lymphoma kinase (ALK); EML4-ALK oncogenic fusion protein; MAP kinase kinase 1 (MAP2K1; MEK1); MAP2K2 (MEK2)

...for the EML4-ALK oncogenic fusion protein . In human lung adenocarcinoma cell lines harboring the EML4-ALK...
...inhibitor of MAP2K1/MAP2K2, to treat advanced or metastatic melanoma. TARGET/MARKER/PATHWAY: Anaplastic lymphoma kinase (ALK) ; EML4-ALK...
BioCentury | Apr 27, 2015
Clinical News

EML4-ALK assay: Clinical trial data

...EML4-ALK assay had 100% specificity for differentiating between the 3 major fusion transcript variants of EML4-ALK...
...is working in a larger series of patients to demonstrate the clinical utility of the EML4-ALK...
...from a blood sample to detect EML4-ALK mutation and oncogenic fusion protein transcripts Indication: Detect EML4-ALK...
Items per page:
1 - 10 of 31